US Pharma MarketingThe post GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid appeared first on Clinical Trials Arena.
GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid
GSK will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS. The post GSK’s drops chronic cough drug, dampening $2bn Bellus Health bid appeared first on Clinical Trials Arena .
GSK will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.
Source: Clinical Trials Arena